Allopurinol

"Allopurinol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Descriptor ID	D000493
MeSH Number(s)	D03.633.100.759.160
Concept/Terms	Allopurinol Allopurinol Uribenz Uribenz Allopurin Allopurin Allorin Allorin Allpargin Allpargin Allural Allural Pan Quimica Apulonga Apulonga Apurin Apurin Atisuril Atisuril Bleminol Bleminol Caplenal Caplenal Capurate Capurate Cellidrin Cellidrin Embarin Embarin Suspendol Foligan Foligan Hamarin Hamarin Lopurin Lopurin Lysuron Lysuron Jenapurinol Jenapurinol Milurit Milurit Milurite Novopurol Novopurol Uripurinol Uripurinol Urosin Urosin Urtias Urtias Xanthomax Xanthomax Uridocid Uridocid Xanturic Xanturic Zygout Zygout Zyloprim Zyloprim Zyloric Pureduct Pureduct Purinol Purinol Progout Progout Remid Remid Rimapurinol Rimapurinol Roucol Roucol Tipuric Tipuric Allohexal Allohexal Allohexan Alloprin Alloprin

Below are MeSH descriptors whose meaning is more general than "Allopurinol".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Purines [D03.633.100.759]
Allopurinol [D03.633.100.759.160]

Below are MeSH descriptors whose meaning is related to "Allopurinol".

Below are MeSH descriptors whose meaning is more specific than "Allopurinol".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Allopurinol" by people in this website by year, and whether "Allopurinol" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2016 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	0	1	1
2015	1	0	1
2016	1	1	2
2020	2	0	2
2021	1	0	1
2023	0	1	1
2024	1	0	1

Below are the most recent publications written about "Allopurinol" by people in Profiles.

Pramar YV. Microbiological Stability of Allopurinol, Clindamycin Hydrochloride, Naltrexone Hydrochloride, Spironolactone and Ursodiol Oral Liquids Compounded in PCCA Base, SuspendIt?. Int J Pharm Compd. 2024 Jul-Aug; 28(4):316-320.

View in: PubMed
Wen YF, Brundage RC, Roman YM, Culhane-Pera KA, Straka RJ. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. Br J Clin Pharmacol. 2023 10; 89(10):2964-2976.

View in: PubMed
Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, Feig DI, Redden DT, Muntner P, Foster PJ, Biggers-Clark SR, Mudano A, Sattui SE, Saddekni MB, Bridges SL, Saag KG. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021 08; 73(8):1514-1522.

View in: PubMed
Pramar YV, Mandal TK, Bostanian LA, Le G, Morris TC, Graves RA. Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt. Int J Pharm Compd. 2020 Sep-Oct; 24(5):413-419.

View in: PubMed
Peng K, Bjork J, Wen YF, Roman YM, Culhane-Pera K, Lo MX, Gertner E, Straka RJ. HLA-B*58: 01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol. Pharmacogenet Genomics. 2020 02; 30(2):21-25.

View in: PubMed
Sakamoto Y, Yamauchi Y, Yasunaga H, Takeshima H, Hasegawa W, Jo T, Matsui H, Fushimi K, Nagase T. Guidelines-concordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation. Respir Investig. 2017 Jan; 55(1):39-44.

View in: PubMed
Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials. 2016 09; 50:238-44.

View in: PubMed
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.

View in: PubMed
Ferrini MG, Moon J, Rivera S, Rajfer J, Gonzalez-Cadavid NF. Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-?1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int. 2012 Feb; 109(4):586-93.

View in: PubMed

People

Explore

Similar Concepts

Top Journals